🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great work by Aisling Barrett. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but interesting assocn seen between regional difference in dox use and outcome. Take home message: if safe to use dox then do use it! #18ICML #ICML25 #lymsm

Evans et al: E-HIPI prognostic score early cHL • Holistic consortium • 1 binary factor: female sex better prog • 3 continuous: max tumour diam, Hb and albumin. Great work from Online calculator now available! #18ICML #ICML25 #lyms

Davison et al - PRO substudy of S1826 substudy. Interesting outputs: • NivoAVD showed more fatigued compared with BV-AVD on treatment but did not meet ‘clin significant’ threshold. • BV-AVD showed excess neuropathy which had a clinically meaningful impact. #ICML25 #lymsm

Dreyfuss et al • ISRT & Pembro in localised relapsed cHL • RT dose varied according to response to Pembro • generally safe & good outcomes • did not seem to impair subseq Rx Consider for older relapsed pts #18ICML #ICML25 #lymsm

Ghesquiere: TIRHOL study of tislelizumab in RR #Hodgkin • 2 cohorts post ASCT or pre • ORR just under 70%: CMR approx 30% • some durable responses Overall a little disappointing as doesn’t reproduce Chinese study with high CMR rate. #18ICML #ICML25 #lymsm

Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim • global Ph 1B • med age 72y • at RP2D, ORR 100%, CRR 80% • no G3+ CRS, 8% ICANs Very impressive results #18ICML #ICML25 #lymsm

Held et al - NIVEAU trial. Nivo-GemOx vs GemOx RR PTCL • 76 pts part of bigger trial • PFS no diff but was ⬆️ when MVA performed • responses ⬆️ • BUT ⬆️ toxic incl ‘infn’ (?hyperinfl state instead); ⬆️ deaths. Doubt there will be further development. #18ICML #ICML25 #lymsm

Fujimoto et al - Allo / auto in ENKT? Japanese data. • if in CR, ASCT appear superior to allo • if in PR, allo appears preferable • no impact on source of allo cells I normally allo these pts in CR1 so potentially practise changing. #18ICML #ICML25 #lymsm

Thurner et al - Optimal >60 less fav • liposomal doc had more neuropathy • PET guided RT to bulk, comparison with Ricover trial showed same results • whole trial did better than Ricover trial Supports omission of RT to initial bulk if PET neg. #18ICML #ICML25 #lymsm

Belada - Epcor mono in older / comorbid DLBCL. • over 80 or 75 with CV risk factors (many simply had HT) • ORR 78% CRR 70% • CR appeared durable • 6 mo PFS 73% • 16% ICANs, 71% CRS Good results but I think many of these could have had anthracycline. #18ICML #ICML25 #lymsm

Wurm-Kuczera: R-pola-glo in unfit 1L DLBCL. Anthacycline ineligible ‘Ix discretion’ • glofit, pola, ritux. Fixed duration • EOT: 90% ORR & 81% CMR • 4% ICANs, G3+ CRS 2.5% V impressive responses. Need to see survival endpoints. #18ICML #ICML25 #lymsm

Tessoulin - tafa, Len, ritux in elderly 1L DLBCL • induction 20mg Len, reduced for consolidation • ORR 72% • but 28% discon due to AE so is toxic #18ICML #ICML25 #lymsm

Lotis-7: loncaT with glofit RR DLBCL Small nos and early data but VERY high response rates with well over 80% CMR rate. One to watch. #18ICML #ICML25 #lymsm

Reinforces that getting patient to ASCT is important. In my view this trumps CAR-T (if chemosensitive of course)

Really hope bispecifics will become available for relapsed mantle.

Zanubrutinib approved for relapsed #MCL by NICE #lymsm Final draft guidance avaliable nice.org.uk/guidance/indev…

What a fascinating thread!

Kamdar et al; 3y FU of TRANSFORM study - Liso-cel vs standard 2nd line in 1st relapse large B-cell NHL. Impressive PFS & EFS benefit Trend to OS but not stat significant. 66% crossed over to liso-cel from control arm. No new tox signal. ascopubs.org/doi/10.1200/JC…